Logo: https://pluri-biotech.com/, Non-free logo, via Wikipedia5
Israeli biotechnology company
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.3Wikipedia text CC BY-SA 4.0
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Out of $1.0M in revenue.6 The company lost money this year.
Financial statements
Revenue11121314156$1.0M in 2026+1781% since 2019Gross profit11121314156$453.0K in 2026+771% since 2019Operating income1112161314156-$24.9M in 2026−30% since 2019Net income1112161314156-$23.8M in 2026−33% since 2019
Revenue171819$167.0K in Q3 FY2026−47% since Q1 FY2025Gross profit171819$56.0K in Q3 FY2026−51% since Q1 FY2025Operating income171819-$6.5M in Q3 FY2026+3% since Q1 FY2025Net income171819-$5.5M in Q3 FY2026−5% since Q1 FY2025
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
Period ending
2026-06-30
2025-06-30
Revenues
$1.0M
$1.3M
Cost of revenues
-$563.0K
-$682.0K
Gross profit
$453.0K
$654.0K
Research and development expenses
-$15.3M
-$14.0M
Less: participation by the NIAID, the IIA (each, as defined below) and Horizon Europe
$214.0K
$1.2M
Research and development expenses, net
-$15.1M
-$12.9M
General and administrative expenses
-$10.3M
-$10.0M
Operating loss
-$24.9M
-$22.2M
Other financial income (expenses), net
$476.0K
-$206.0K
Interest expense
-$932.0K
-$873.0K
Total financial income (expenses), net
-$456.0K
-$1.1M
Loss before taxes
-$25.4M
-$23.3M
Tax benefit
$25.0K
$5.0K
Net loss
-$25.4M
-$23.2M
Net loss attributed to non-controlling interests
-$1.5M
-$667.0K
Net loss attributed to shareholders
-$23.8M
-$22.6M
Basic loss per share (in Dollars per share)
-$2.44
-$3.56
Diluted loss per share (in Dollars per share)
-$2.44
-$3.56
Weighted average number of shares used in computing basic loss per share (in Shares)
9.7M shares
6.3M shares
Weighted average number of shares used in computing diluted loss per share (in Shares)
Total assets171819$26.1M in Q3 FY2026−23% since Q1 FY2025Shareholders’ equity171819-$18.6M in Q3 FY2026+64% since Q1 FY2025Cash171819$3.4M in Q3 FY2026−20% since Q1 FY2025
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.6
Period ending
2026-06-30
2025-06-30
2024-06-30
Cash and cash equivalents
$3.5M
$5.9M
Short-term bank deposits
$4.3M
$14.7M
Restricted cash
$29.0K
$422.0K
Customer receivables, net
$87.0K
$236.0K
Prepaid expenses and other current assets
$810.0K
$824.0K
Total current assets
$8.7M
$22.1M
Restricted bank deposits
$1.0M
$879.0K
Severance pay fund
$702.0K
$610.0K
Property and equipment, net
$1.6M
$1.8M
Advances for property and equipment
$861.0K
$420.0K
Intangible assets, net
$2.6M
$2.8M
Goodwill
$3.1M
$3.1M
Operating lease right-of-use asset
$6.2M
$6.9M
Other long-term assets
$88.0K
$27.0K
Total long-term assets
$16.1M
$16.6M
Total assets
$24.9M
$38.7M
Trade payables
$702.0K
$866.0K
Accrued expenses
$928.0K
$1.2M
Operating lease liability
$996.0K
$659.0K
Accrued vacation and recuperation
$911.0K
$859.0K
Advances from customers
$68.0K
$148.0K
Loan from the European Investment Bank, or EIB
$27.4M
$27.3M
Other accounts payable
$1.7M
$1.3M
Total current liabilities
$32.7M
$32.3M
Accrued severance pay
$678.0K
$703.0K
Operating lease liability
$6.5M
$6.1M
Deferred tax liabilities
$384.0K
$415.0K
Simple Agreement for Future Equity, or SAFE
$794.0K
Advance towards share subscription
$1.2M
Total long-term liabilities
$9.6M
$7.2M
Additional paid-in capital
$443.8M
$436.2M
Accumulated deficit
-$466.9M
-$443.1M
Total shareholders deficit
-$23.0M
-$6.8M
Non-controlling interests
$5.6M
$6.0M
Total deficit
-$17.4M
-$865.0K
$5.4M
Total liabilities and deficit
$24.9M
$38.7M
Common shares, par value per share (in Dollars per share)
$0.00
$0.00
Common shares, authorized (in Shares)
37.5M shares
37.5M shares
Common shares, issued (in Shares)
10.8M shares
7.9M shares
Common shares, outstanding (in Shares)
10.8M shares
7.9M shares
Period ending
2026-06-30
2025-06-30
2024-06-30
Cash and cash equivalents
$3.5M
$5.9M
Short-term bank deposits
$4.3M
$14.7M
Restricted cash
$29.0K
$422.0K
Customer receivables, net
$87.0K
$236.0K
Prepaid expenses and other current assets
$810.0K
$824.0K
Total current assets
$8.7M
$22.1M
Restricted bank deposits
$1.0M
$879.0K
Severance pay fund
$702.0K
$610.0K
Property and equipment, net
$1.6M
$1.8M
Advances for property and equipment
$861.0K
$420.0K
Intangible assets, net
$2.6M
$2.8M
Goodwill
$3.1M
$3.1M
Operating lease right-of-use asset
$6.2M
$6.9M
Other long-term assets
$88.0K
$27.0K
Total long-term assets
$16.1M
$16.6M
Total assets
$24.9M
$38.7M
Trade payables
$702.0K
$866.0K
Accrued expenses
$928.0K
$1.2M
Operating lease liability
$996.0K
$659.0K
Accrued vacation and recuperation
$911.0K
$859.0K
Advances from customers
$68.0K
$148.0K
Loan from the European Investment Bank, or EIB
$27.4M
$27.3M
Other accounts payable
$1.7M
$1.3M
Total current liabilities
$32.7M
$32.3M
Accrued severance pay
$678.0K
$703.0K
Operating lease liability
$6.5M
$6.1M
Deferred tax liabilities
$384.0K
$415.0K
Simple Agreement for Future Equity, or SAFE
$794.0K
Advance towards share subscription
$1.2M
Total long-term liabilities
$9.6M
$7.2M
Additional paid-in capital
$443.8M
$436.2M
Accumulated deficit
-$466.9M
-$443.1M
Total shareholders deficit
-$23.0M
-$6.8M
Non-controlling interests
$5.6M
$6.0M
Total deficit
-$17.4M
-$865.0K
$5.4M
Total liabilities and deficit
$24.9M
$38.7M
Common shares, par value per share (in Dollars per share)
$0.00
$0.00
Common shares, authorized (in Shares)
37.5M shares
37.5M shares
Common shares, issued (in Shares)
10.8M shares
7.9M shares
Common shares, outstanding (in Shares)
10.8M shares
7.9M shares
Cash from operations1112161314156-$19.6M in 2026−33% since 2019Capital spending1112161314156$633.0K in 2026+165% since 2019Free cash flow1112161314156-$20.2M in 2026−32% since 2019
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
Period ending
2026-06-30
2025-06-30
Net loss
-$25.4M
-$23.2M
Depreciation and amortization
$511.0K
$316.0K
Loss on property and equipment
$13.0K
Share-based compensation to employees, directors and non-employee consultants
$3.7M
$2.1M
Increase in fair value of simple agreement for future equity, or SAFE, liability
$80.0K
Decrease in fair value of warrant and pre-funded warrant liability
-$556.0K
Decrease (increase) in customer receivable, net
$149.0K
-$202.0K
Decrease (increase) in prepaid expenses, other current assets and other long-term assets
-$47.0K
$1.0K
Decrease in trade payables
-$77.0K
-$235.0K
Increase in other accounts payable, accrued vacation and recuperation, deferred tax liabilities and accrued expenses
$124.0K
$377.0K
Increase (decrease) in advances from customers
-$80.0K
$105.0K
Increase in operating lease right-of-use asset and liability, net
$1.5M
$834.0K
Decrease in interest receivable on short-term deposits and restricted bank deposits
$27.0K
$91.0K
Effect of exchange rate changes on cash, cash equivalents, deposits, restricted cash and restricted bank deposits
-$128.0K
-$1.1M
Increase in short-term interest payable and exchange rate differences related to the EIB loan, net
$142.0K
$3.3M
Decrease in accrued severance pay, net
-$117.0K
-$42.0K
Net cash used for operating activities
-$19.6M
-$18.2M
Purchase of property and equipment
-$633.0K
-$1.6M
Proceeds from sale of property and equipment
$18.0K
Proceeds from short-term deposits, net
$10.5M
$9.3M
Cash related to the Kokomodo Transaction (defined below)
$373.0K
Net cash provided by investing activities
$9.9M
$8.0M
Issuance of common shares, pre-funded warrants and warrants, net of issuance costs
$5.1M
$9.6M
Proceeds from the advance towards share subscription
$1.2M
Issuance costs related to issuance of shares in the Kokomodo Transaction (defined below)
-$47.0K
Proceeds from SAFE
$714.0K
Net cash provided by financing activities
$7.0M
$9.5M
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
$27.0K
$177.0K
Decrease in cash, cash equivalents, restricted cash and restricted bank deposits
-$2.6M
-$475.0K
Purchase of property and equipment on credit
$3.0K
$90.0K
The Kokomodo Transaction (defined below)
$4.7M
Lease liabilities arising from obtaining right-of-use assets
Pluri Inc. sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Pluri Inc.
Chutzpah Holdings LtdFiled SCHEDULE 13D/A on Pluri Inc., latest Jul 1, 2026 (6 filings since Feb 12, 2025)
Shayna LPFiled SCHEDULE 13G/A on Pluri Inc., latest Oct 14, 2025 (4 filings since Feb 16, 2023)
Chen Franco-YehudaFiled SCHEDULE 13D/A on Pluri Inc., latest Jun 9, 2025
Yaky YanayFiled SCHEDULE 13D/A on Pluri Inc., latest May 20, 2025 (2 filings since Jan 4, 2023)
John A. Gunn Filed SCHEDULE 13G on Pluri Inc., latest Feb 14, 2024
David Mark SlagerFiled SC 13G/A on Pluri Inc., latest Feb 1, 2024 (3 filings since Jan 26, 2022)
Pluri Inc.Reno, Nevada, United States
Fishway BV, incorporated under the laws of Subsidiary · Belgium
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Pluri Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Our principal executive, manufacturing and research and development offices are located at MATAM Advanced Technology Park, Building No. 5, Haifa, Israel, where we occupy approximately 4,389 square meters. This space facilitates operations for Pluri, Pluri Biotech, Coffeesai, Kokomodo and Cellav. In addition, Ever After Foods, a majority-held subsidiary of Pluri Biotech, occupies a separate office space located at 1 Netiv HaOr street, Haifa, Israel, comprising approximately 655 square meters. Our gross monthly rent payment for these leased facilities as of June 30, 2026, was 390,000 NIS (approximately $123,000). For fiscal year 2026, we recognized expense in the amount of $1,095,000, according to the implementation of Accounting Standards Update No. 2016-02, “Leases.”
We believe that the current space that we and our Subsidiaries occupy sufficiently supports the operational requirements at present and for the foreseeable future.
Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of a stem cell patent which was developed during his Ph.D. studies at The Rappaport Faculty Of Medicine, Technion, under the supervision of Dr. Shosh Merchav, together with Professors Dov Zipori and Avinoam Kadouri from the Weizmann Institute of Science.
In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents belonging to Pluristem and changed its name to Pluristem Life Systems. In 2007 the name was changed again, this time to Pluristem Therapeutics Inc. Pluristem's shares are traded on the NASDAQ exchange and the Tel Aviv Stock Exchange, as well as on the Frankfurt Stock Exchange.
In December 2020, the Genesis Prize and Start-up Nation Central named Pluri as one of the winners in a competition among Israeli high-tech and biotechnology companies.
In July 2022, the company changed its name from Pluristem Therapeutics to Pluri Inc. and its ticker symbol to PLUR from PSTI.
DirectorDoron Birger named Dec 30, 2022 to Mar 19, 202547
DirectorMaital Shemesh-Ramussen named Mar 19, 202547
Products and brands
Pluristem is in the process of clinically testing the use of its PLX (PLacental eXpanded) cells in Phase I, Phase II and Phase III trials. A Phase III trial of PLX-(PAD)-peripheral arterial disease cells in the treatment of critical limb ischemia has been cleared to start enrolling patients by the U.S. Food and Drug Administration. The Phase III trial has also been cleared by regulators in Germany and the United Kingdom. Pluristem has completed enrollment of 172 patients in January 2017 for a multinational Phase II clinical trial of its PLX-PAD treatment pertaining to intermittent claudication. Results from the study suggest that PLX-R18 is safe and may significantly improve outcomes after bone marrow failure or hematopoietic cell transplantation. The U.S. Food and Drug Administration has also cleared Pluristem to commence patient enrollment in a Phase I trial of its PLX-R18 cells to treat insufficient hematopoietic recovery following bone marrow transplant.
PLX-R18 were initially developed with Professor Raphael Gorodetsky at Hadassah Hospital for the treatment of acute radiation syndrome and enhancement of bone marrow regeneration. The U.S. National Institutes of Health is currently evaluating Pluristem's PLX-R18 cells as a treatment for acute radiation syndrome. The dose finding portion of the study was successfully concluded and data showed that PLX-R18 treated subjects had an 85% survival rate compared to the placebo group which had a 50% survival rate. PLX-R18 can serve as a tool for governments to protect their citizens against potential exposure to nuclear radiation.
In May 2012, Pluristem reported that its experimental PLacental eXpanded cells were injected into the muscles of a 7-year-old Romanian girl undergoing treatment for bone marrow aplasia disease at the Hadassah Medical Center in Jerusalem. The girl had undergone two allogenic stem cell transplants since being admitted in August 2011, both of which failed to improve her condition. Two months thereafter, with the patient's condition deteriorating rapidly, the Director of Bone Marrow Transplantation, Cell Therapy and Transplantation Research Center at Hadassah felt that all available options had been exhausted and turned to Pluristem's PLX cells. The Helsinki committee at Israel's Ministry of Health approved the procedure under compassionate use. According to Pluristem CEO Zami Aberman, it was the first time ever that stem cells were injected into the muscle rather than into the body's blood system. Pluristem announced that the treatment led to a significant increase in the girl's red cells, white cells and platelets, effecting a reverse in her condition. She was released from the hospital soon after Pluristem's announcement.
In September 2012 Pluristem reported saving the life of a third bone marrow disease patient using its PLacental eXpanded cell treatment, again at Jerusalem's Hadassah Medical Center and again under the terms of compassionate use. The 45-year-old patient suffered from acute myeloid leukemia and pancytopenia, and his condition was determined to be life-threatening. After two intramuscular injections of Pluristem's PLX cells, the patient's condition improved significantly and he was released from the hospital. This event has been used as a supporting reference to the medical potential of the PLX cells.
Read the full text
In January 2016, the US Food and Drug Administration (FDA) gave Pluristem Therapeutics the go-ahead to move forward with its innovative treatment approach for hematopoietic disorders. Pluristem was given permission to begin its Phase I trial of PLX-R18 cells to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation. The clinical trial is expected to begin in the coming months.
In 2020 Pluristem began treating COVID-19 patients with placenta cells known as PLX.
On May 8, 2020, the United States Food and Drug Administration approved Pluristem's application to conduct a Phase II study of its PLX cells (as described by HospiMedica.com, "PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties that induce the immune system's natural regulatory T cells and M2 macrophages, and thus may prevent or reverse the dangerous overactivation of the immune system. Previous pre-clinical findings of PLX cells revealed therapeutic benefit in the treatment of severe Covid-19 cases").
Nov 11, 2026Reports results for the quarter ending Sep/202660
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
191 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 41 insider forms, 20 large holders, 3 private raises, 47 other. The latest 20:
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
Where the company's money came from, by calendar year: private offerings filed with the SEC,
federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA.
Each bar links to the records below.
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Aug 28, 2026Raised $3.7 million in a private offering of securities46Form D: 1 investor so farForm D
Feb 3, 2025Raised $3.5 million in a private offering of equity47Form D: 1 investor so farForm D
Dec 13, 2022Raised $8.5 million in a private offering of equity69Form D: 14 investors so farForm D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
From the cover page of the 10-K filed Sep 10, 2026 (Section 12(b) of the Exchange Act).20
Risk factors and legal proceedings
The risks Pluri Inc. names in Item 1A of its 10-K filed Sep 10, 2026: 48 risks under these headings, as written.20
Risks Related to Our Business
Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included in this Annual Report. The financial statements have been prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result if we are unable to continue as a going concern.
We may need to raise additional financing to support the research, development and manufacturing of our cell-based products in the future, but we cannot be sure we will be able to obtain additional financing on terms favorable to us when needed. If we are unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated.
Our likelihood of profitability depends on our ability to license and/or develop and commercialize our products based on our technology, which is currently in the development stage. If we are unable to complete the development and commercialization of our cell-based products and CDMO services successfully, or are unable to obtain the necessary regulatory approvals, our likelihood of profitability will be limited severely.
We have not generated significant or consistent revenues to date, which raises doubts with respect to our ability to generate revenues in the future.
Failure to reach an agreement with the EIB about the repayment of the EIB Loan could adversely affect our financial condition and liquidity.
Because most of our officers and directors are located in non-U.S. jurisdictions, you may have no effective recourse against the management for misconduct and may not be able to enforce judgment and civil liabilities against our officers, directors, experts and agents.
While we may seek partners for licensing deals, joint ventures, partnerships, and direct sale of our products in various industries, there is no guarantee we will be successful in doing so.
Changes in U.S. trade policy and tariffs may have an adverse impact on our business.
Risks Related to Development, Clinical Studies, and Regulatory Approval of Our Product Candidates
If we are not able to conduct our clinical trials properly and on schedule, marketing approval by FDA, EMA, MOH and other regulatory authorities may be delayed or denied.
The results of our clinical trials may not support our product candidates’ claims or any additional claims we may seek for our product candidates, and our clinical trials may result in the discovery of adverse side effects.
The other 37 risks
Favorable results from compassionate use treatment or initial interim results from a clinical trial do not ensure that later clinical trials will be successful and success in early-stage clinical trials does not ensure success in later-stage clinical trials.
Our product development programs are based on novel technologies and are inherently risky.
Our cell therapy drug candidates represent new classes of therapy that the marketplace may not understand or accept.
Interim, “top-line,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures, which could result in material changes in the final data.
Risks Related to Our Longevity, Wellness and Aesthetics Business
Our longevity, wellness and aesthetics products may not achieve market acceptance, and we have limited operating and commercialization history in this business. Regulatory uncertainty and the potential for differing product classifications could subject these products to additional requirements and adversely affect our ability to commercialize them.
Risks Related to Our Cultivated FoodTech Business
Ever After Foods has a limited operating history in the field of cultivated meat and is seeking to expand its capabilities to additional cultivated protein and seafood applications, including through the recently announced Fishway Acquisition. To-date, Ever After Foods and its prospects are, and are expected to continue being, dependent on its ability to meet a number of challenges.
Ever After Foods is primarily focused on utilizing its technology for the development of cultivated meat, and it has limited data on the performance of our and its technologies in the field of cultivated meat to date.
Consumer preferences for alternative proteins in general, and more specifically cultivated meats, are difficult to predict and may change, and, if we are unable to respond quickly to new trends, Ever After Foods’ business may be adversely affected.
We expect that products utilizing Ever After Foods’ technologies will be subject to regulations that could adversely affect Ever After Foods’ business and operations.
Any changes in, or changes in the interpretation of, applicable laws, regulations or policies of the USDA, state regulators or similar foreign regulatory authorities that relate to the use of the terms “meat” or “poultry” or other similar terms in connection with cultivated meat products could adversely affect our business, prospects, results of operations or financial condition.
Our various new lines of business, including our plant-based vertical (e.g. Coffeesai and Kokomodo), and Ever After Foods, are new businesses with limited operating activity to date, and their success is dependent on the ability to deliver a high-quality product while overcoming multiple challenges.
We may need to raise additional financing to support our biopharming and plant-based business vertical and the research, development and manufacturing of their respective products. If we are unable to obtain additional financing to meet their needs, their operations may be adversely affected or terminated.
Cultivated plant-based products utilizing our 3D cell expansion technology may be subject to regulations that could adversely affect its business and results of operations.
Risks Related to Commercialization of Our Product Candidates
We may not successfully establish new collaborations, joint ventures or licensing arrangements, which could adversely affect our ability to develop and commercialize our product candidates.
The market for our cell therapy products will be heavily dependent on third party reimbursement policies.
Risks Related to Intellectual Property
Our success depends in large part on our ability to develop and protect our technology and our cell therapy products. If our patents and proprietary rights agreements do not provide sufficient protection for our technology and our cell therapy products, our business and competitive position will suffer.
Third parties may initiate legal proceedings alleging that we are infringing their IP rights, the outcome of which would be uncertain and could have a material adverse effect on our business.
The patent approval process is complex, and we cannot be sure that our pending patent applications or future patent applications will be approved.
Risks Related to Our Common Shares
The price of our common shares may fluctuate significantly.
We could fail to regain compliance with Nasdaq Listing Rules and to maintain the listing of our common shares on Nasdaq, which could seriously harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction.
Future sales of our common shares may cause dilution.
Shareholder activism, proxy contests, shareholder proposals and other efforts by shareholders to influence our business, strategy, governance or Board composition could disrupt our business and adversely affect our results of operations and the market price of our common shares
Beneficial ownership information may be incomplete, delayed or inaccurate because it depends on information reported by our shareholders and in SEC filings.
Risks Related to Foreign Exchange Rates
We are exposed to fluctuations in currency exchange rates.
Our cash may be subject to a risk of loss.
Risks Related to Our Industries
If we do not keep pace with our competitors and with technological and market changes, our technology and products may become obsolete, and our business may suffer.
Potential product liability claims could adversely affect our future earnings and financial condition.
Risks Related to Our Dependence on Third Parties
We are dependent upon third party suppliers and service providers for raw materials, components, consumables, cleaning and sanitation materials, equipment, utilities and complementary services needed to manufacture PLX, provide CDMO services and support our longevity, wellness and aesthetics business; if any of these third parties fails or is unable to perform in a timely manner, our ability to manufacture products, provide services and satisfy our obligations to customers may be compromised.
A cybersecurity incident, other technology disruptions, risks associated with artificial intelligence (“AI”), or failure to comply with laws and regulations relating to privacy and the protection of data relating to individuals, could negatively impact our business and our reputation.
Failure to comply with certain European privacy regulations could have an adverse effect on our business and reputation.
We may be exposed to liabilities under the Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act could have a material adverse effect on our business.
Since we received grants from the IIA, we are subject to on-going restrictions.
Recent global inflation may adversely affect our business results.
Non-compliance with environmental, social, and governance (“ESG”) practices could harm our reputation, or otherwise adversely impact our business, while increased attention to ESG initiatives could increase our costs.
Since we have signed the EIB Finance Agreement, we agreed to guaranty the loan as well as agreed to limitations that require us to notify the EIB, and in some cases obtain their approval, before we engage with other banks for additional sources of funding or with potential partners for certain strategic activities.
Our principal research and development and manufacturing facilities are located in Haifa, Israel and military conditions in Israel, including the armed conflict between Israel and terrorist organizations from the Gaza Strip, Lebanon and Yemen, tensions with regional countries hostile to Israel such as Iran - may cause interruption or suspension of our business operations without warning.
The potential assignment of the EIB Loan to a third party and the potential conversion of such indebtedness our securities in the future, if such third party is a related party, may create conflicts of interest, or the perception of such conflicts of interest, and may result in terms that are not as favorable to us as those that could be obtained in an arm’s-length transaction.
